Pharma-Planta: road testing the developing regulatory guidelines for plant-made pharmaceuticals
Related Experiment Video
Updated: Jul 17, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
Penelope Amelia Claire Sparrow1, Judith A Irwin, Phil J Dale
1John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, UK. penelope.sparrow@bbsrc.ac.uk
Abstract:
Significant advances over the last few years have seen plant-made pharmaceuticals (PMPs) move from the exploratory research phase towards clinical trials, with the first commercial products for human use expected to reach the market by 2009. Europe has yet to witness the commercial application of PMP technology, although at least one product has begun phase II clinical trials with others following close behind. These emerging products are set to challenge the complex and overlapping regulations that currently govern GM plants and 'conventional' pharmaceutical production. The areas of responsibility are being mapped out between the different EU regulatory agencies, with specific guidelines currently being drawn up for the regulation of PMPs. This article discusses issues surrounding the development of robust risk-assessment and risk-management practices based on health and environmental impact, while working with EU regulatory authorities to ensure appropriate regulatory oversight.
Related Concept Videos
Preclinical Development: Overview
Drug Regulation
Clinical Trials: Overview
Clinically Relevant Drug Product Specifications: Methods of Establishment
In Vitro Drug Release Testing: Overview, Development and Validation
Production of Pharmaceuticals

